RT期刊文章SR电子T1预测出血后体积和残疾Perimesencephalic蛛网膜下腔出血(P02.227)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP P02.227 OP P02.227 VO 78是1补充A1安德鲁Naidech A1尼尔首页·罗森博格A1马修马斯河A1伯纳德Bendok A1 h . Batjer A1亚历山大Nemeth年2012 UL //www.ez-admanager.com/content/78/1_Supplement/P02.227.abstract AB目的:我们的目的是确定减少血小板活动门票和引流静脉异常与蛛网膜下腔出血(SAH)体积大。背景蛛网膜下腔出血体积和非典型模式的决定因素的血液尚不清楚。设计/方法:我们前瞻性地确定non-comatose SAH患者没有可识别的动脉瘤。我们经常测量血小板活动并记录服用阿司匹林的承认。SAH卷计算与验证技术。综述了CT血管造影检查的认证neuroradiologist引流静脉。随访观察患者的临床结果通过与修改后的3个月内兰金规模(夫人)。数据(Q1-Q3)。结果:有31例队列。30(97%)接受了血管造影在承认,和25(81%)额外的延迟血管造影。SAH最低成交量与正常静脉引流双边(4.4[3.7 - -16.4]毫升)和高(12.9[3.7—-20.4])或两个(20.9毫升(12.5 - -34.6),P = 0.03)间断静脉流域。减少血小板活动有更多的SAH患者诊断CT, 17.5(10.6 - 20.9)和6.1毫升(2.3 - 15.3)(P = 0.046)。 SAH volume was greater for patients requiring drainage for hydrocephalus 16.4 [11.5 – 20.5] vs. 5.4 [2.7 – 16.4] mL (P=0.009). Outcomes at three months were generally excellent (median mRS=0, no symptoms).Conclusions: Discontinuous venous drainage and reduced platelet activity were associated with increased SAH volume and hydrocephalus. These factors may explain thick SAH and reduce the need for repeated invasive imaging in such patients.Supported by: This work was departmentally funded.Disclosure: Dr. Naidech has received research support from Gaymar Inc. Dr. Rosenberg has nothing to disclose. Dr. Maas has nothing to disclose. Dr. Bendok has nothing to disclose. Dr. Batjer has nothing to disclose. Dr. Nemeth has nothing to disclose.Tuesday, April 24 2012, 07:30 am-12:00 pm